It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Gelatin-methacryloyl (GelMA) is a highly adaptable biomaterial extensively utilized in skin regeneration applications. However, it is frequently imperative to enhance its physical and biological qualities by including supplementary substances in its composition. The purpose of this study was to fabricate and characterize a bi-layered GelMA-gelatin scaffold using 3D bioprinting. The upper section of the scaffold was encompassed with keratinocytes to simulate the epidermis, while the lower section included fibroblasts and HUVEC cells to mimic the dermis. A further step involved the addition of amniotic membrane extract (AME) to the scaffold in order to promote angiogenesis. The incorporation of gelatin into GelMA was found to enhance its stability and mechanical qualities. While the Alamar blue test demonstrated that a high concentration of GelMA (20%) resulted in a decrease in cell viability, the live/dead cell staining revealed that incorporation of AME increased the quantity of viable HUVECs. Further, gelatin upregulated the expression of KRT10 in keratinocytes and VIM in fibroblasts. Additionally, the histological staining results demonstrated the formation of well-defined skin layers and the creation of extracellular matrix (ECM) in GelMA/gelatin hydrogels during a 14-day culture period. Our study showed that a 3D-bioprinted composite scaffold comprising GelMA, gelatin, and AME can be used to regenerate skin tissues.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Tehran University of Medical Sciences, Department of Tissue Engineering, School of Advanced Technologies in Medicine, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922); Universal Scientific Education and Research Network (USERN), AstraBionics Research Network (ARN), Tehran, Iran (GRID:grid.510410.1) (ISNI:0000 0004 8010 4431)
2 Semnan University of Medical Sciences, Department of Tissue Engineering and Applied Cell Sciences, School of Medicine, Semnan, Iran (GRID:grid.486769.2) (ISNI:0000 0004 0384 8779)
3 Tarbiat Modares University, Material Engineering Department, Faculty of Engineering, Tehran, Iran (GRID:grid.412266.5) (ISNI:0000 0001 1781 3962)
4 University of Tehran, Department of Life Science Engineering, Faculty of New Science and Technologies, Tehran, Iran (GRID:grid.46072.37) (ISNI:0000 0004 0612 7950)
5 Tehran University of Medical Sciences, Department of Tissue Engineering, School of Advanced Technologies in Medicine, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922)
6 ACECR, Department of Stem Cells and Developmental Biology, Cell Sciences Research Center, Royan Institute for Stem Cell Biology and Technology, Tehran, Iran (GRID:grid.419336.a) (ISNI:0000 0004 0612 4397)
7 Tehran University of Medical Sciences, Department of Tissue Engineering, School of Advanced Technologies in Medicine, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922); Universal Scientific Education and Research Network (USERN), Regenerative Medicine Group (REMED), Tehran, Iran (GRID:grid.510410.1) (ISNI:0000 0004 8010 4431)